SIM
ABBV icon

Studio Investment Management’s AbbVie ABBV Stock Holding History

Studio Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125
Closed -$26.2K – 174
2025
Q1 		$26.2K Buy
125
+40
+47% +$7.78K 0.01% 225
2024
Q4 		$15.1K Hold
85
– – ﹤0.01% 241
2024
Q3 		$16.8K Hold
85
– – ﹤0.01% 234
2024
Q2 		$14.6K Hold
85
– – ﹤0.01% 228
2024
Q1 		$15.5K Hold
85
– – ﹤0.01% 227
2023
Q4 		$13.2K Sell
85
-15
-15% -$2.19K ﹤0.01% 214
2023
Q3 		$14.9K Hold
100
– – ﹤0.01% 198
2023
Q2 		$13.5K Hold
100
– – ﹤0.01% 196
2023
Q1 		$15.9K Hold
100
– – ﹤0.01% 184
2022
Q4 		$16.2K Buy
+100
New +$15.3K 0.01% 155

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Studio Investment Management's ABBV Position: Q2 2025 in Review

Studio Investment Management sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 125 shares — an estimated $26.2K sold.

Studio Investment Management first reported a position in ABBV in Q4 2022 and held it in 10 quarters. The position peaked at $26.2K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Studio Investment Management reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Studio Investment Management sold 125 AbbVie shares in Q2 2025, an estimated $26.2K.
  • Studio Investment Management first reported a position in AbbVie in Q4 2022 and held it in 10 quarters.
  • Studio Investment Management's AbbVie position peaked at $26.2K in Q1 2025.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Studio Investment Management's 13F filing for Q2 2025, filed 30 Jul 2025.